Lessons learned from development of docetaxel

Bibliography

• Karantanis E, Nicholson S, Morris DL. Taxotere inhibits in vitro growth of human colonic cancer cell lines. Eur J Surg Oncol 1994;20(6):653-7
   PubMedGoogle Scholar
• Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30(6):444-50
   PubMed Web of Science ®Google Scholar
• Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79(2):196-202
   PubMedGoogle Scholar
• Rangel C, Niell H, Miller A, Cox C. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 1994;33(6):460-4
   PubMed Web of Science ®Google Scholar
• Riccardi A, Servidei T, Tornesello A, et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995;31A(4):494-9
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Zaffaroni N, Orlandi L, Oriana S. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 1993;11(6):528-35
   PubMed Web of Science ®Google Scholar
• Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996;32A(2):226-30
   PubMed Web of Science ®Google Scholar
• Consolini R, Pui CH, Behm FG, et al. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 1998;16(3):907-13
   PubMed Web of Science ®Google Scholar
• Dykes DJ, Bissery MC, Harrison SD Jr, Waud WR. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995;13(1):1-11
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;9(1):1-17
   PubMed Web of Science ®Google Scholar
• Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I. Preclinical experience. Anticancer Drugs 1995;6(3):339-55, 63-8
   PubMed Web of Science ®Google Scholar
• Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53(3):523-7
   PubMed Web of Science ®Google Scholar
• Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11(5):950-8
   PubMed Web of Science ®Google Scholar
• Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992;84(23):1781-8
   PubMed Web of Science ®Google Scholar
• Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12(7):1458-67
   PubMed Web of Science ®Google Scholar
• Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53(5):1037-42
   PubMed Web of Science ®Google Scholar
• Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surviv 1993;17:305-13
   PubMedGoogle Scholar
• ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A Phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5(6):527-32
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Burris HA 3rd, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13(12):2879-85
   PubMed Web of Science ®Google Scholar
• Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13(12):2886-94
   PubMed Web of Science ®Google Scholar
• Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996;73(2):210-6
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10(24):8147-51
   PubMed Web of Science ®Google Scholar
• Hahn NM, Marsh S, Fisher W, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006;12(20 Pt 1):6094-9
   PubMed Web of Science ®Google Scholar
• Nagao S, Fujiwara K, Oda T, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol 2005;96(3):805-9
   PubMed Web of Science ®Google Scholar
• Garcia AA, Blessing JA, Vaccarello L, Roman LD. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;30(4):428-31
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991-7
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25(22):3210-6
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704
   PubMed Web of Science ®Google Scholar
• Alexandre J, Bleuzen P, Bonneterre J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18(3):562-73
   PubMed Web of Science ®Google Scholar
• Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005;41(8):1117-26
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Androulakis N, Kotsakis A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 2008;59(1):57-63
   PubMed Web of Science ®Google Scholar
• Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24(36):5664-71
   PubMed Web of Science ®Google Scholar
• Markman M. Managing taxane toxicities. Support Care Cancer 2003;11(3):144-7
   PubMed Web of Science ®Google Scholar
• Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004;44(3):363-8
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993;4(7):610-1
   PubMed Web of Science ®Google Scholar
• Rosing H, Lustig V, Koopman FP, et al. Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B Biomed Sci Appl 1997;696(1):89-98
   PubMed Web of Science ®Google Scholar
• Vergniol JC, Bruno R, Montay G, Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 1992;582(1-2):273-8
   PubMed Web of Science ®Google Scholar
• Loos WJ, Verweij J, Nooter K, et al. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;693(2):437-41
   PubMedGoogle Scholar
• Ciccolini J, Catalin J, Blachon MF, Durand A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J Chromatogr B Biomed Sci Appl 2001;759(2):299-306
   PubMed Web of Science ®Google Scholar
• Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000;748(2):383-8
   PubMed Web of Science ®Google Scholar
• Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783(1):231-6
   PubMed Web of Science ®Google Scholar
• Wang LZ, Goh BC, Grigg ME, et al. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003;17(14):1548-52
   PubMed Web of Science ®Google Scholar
• Kuppens IE, van Maanen MJ, Rosing H, et al. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005;19(5):355-61
   PubMed Web of Science ®Google Scholar
• Gustafson DL, Long ME, Zirrolli JA, et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 2003;52(2):159-66
   PubMed Web of Science ®Google Scholar
• Zufia Lopez L, Aldaz Pastor A, Aramendia Beitia JM, et al. Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. Ther Drug Monit 2006;28(2):199-205
   PubMed Web of Science ®Google Scholar
• Mortier KA, Lambert WE. Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry. J Chromatogr A 2006;1108(2):195-201
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Zhao M, Brahmer JR, et al. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;773(2):183-90
   PubMed Web of Science ®Google Scholar
• Urien S, Barre J, Morin C, et al. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996;14(2):147-51
   PubMed Web of Science ®Google Scholar
• Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993;80(3):337-44
   PubMedGoogle Scholar
• ten Tije AJ, Loos WJ, Zhao M, et al. Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 2004;15(7):715-8
   PubMed Web of Science ®Google Scholar
• Minami H, Kawada K, Sasaki Y, et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci 2006;97(3):235-41
   PubMed Web of Science ®Google Scholar
• Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77(1):43-53
   PubMed Web of Science ®Google Scholar
• Hooker A, Ten Tije A, Carducci M, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P450 3A activity measurements. Clin Pharmacol Ther 2008;1-8 (online published January 9, 2008)
   Google Scholar
• Loos WJ, Baker SD, Verweij J, et al. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003;74(4):364-71
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Beijnen JH, Verweij J, et al. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999;5(10):2918-24
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19(2):125-41
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36(2):99-114
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996;24(6):655-8
   PubMed Web of Science ®Google Scholar
• Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56(6):1296-302
   PubMed Web of Science ®Google Scholar
• Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6(4):1255-8
   PubMed Web of Science ®Google Scholar
• Alexandre J, Rey E, Girre V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007;18(1):168-72
   PubMed Web of Science ®Google Scholar
• Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20(17):3683-90
   PubMed Web of Science ®Google Scholar
• Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56(1);:58-65
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Tamura T, Kamiya Y, et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000;18(11):2301-8
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Nooter K, et al. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6(7):2598-603
   PubMed Web of Science ®Google Scholar
• McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998;42(2):155-9
   PubMed Web of Science ®Google Scholar
• Baille P, Bruno R, Schellens JH, et al. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 1997;3(9):1535-8
   PubMed Web of Science ®Google Scholar
• Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004;40(8):1170-8
   PubMed Web of Science ®Google Scholar
• Hochegger K, Lhotta K, Mayer G, et al. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant 2007;22(1):289-90
   PubMedGoogle Scholar
• ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23(6):1070-7
   PubMed Web of Science ®Google Scholar
• Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104(12):2766-74
   PubMed Web of Science ®Google Scholar
• Kaira K, Tsuchiya S, Sunaga N, et al. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol 2007;30(1):51-6
   PubMed Web of Science ®Google Scholar
• Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12(20 Pt 1):6100-5
   PubMed Web of Science ®Google Scholar
• LeCaer H, Barlesi F, Robinet G, et al. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: the GFPC 02-02b study. Lung Cancer 2007;57(1):72-8
   PubMed Web of Science ®Google Scholar
• Takigawa N, Segawa Y, Kishino D, et al. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004;54(3):230-6
   PubMed Web of Science ®Google Scholar
• Duche JC, Urien S, Simon N, et al. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000;33(3):197-202
   PubMed Web of Science ®Google Scholar
• Bruno R, Olivares R, Berille J, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003;9(3):1077-82
   PubMed Web of Science ®Google Scholar
• Charles KA, Rivory LP, Stockler MR, et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet 2006;45(6):611-22
   PubMed Web of Science ®Google Scholar
• Puisset F, Alexandre J, Treluyer JM, et al. Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 2007;97(3):290-6
   PubMed Web of Science ®Google Scholar
• Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-80
   PubMed Web of Science ®Google Scholar
• Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006;12(19):5786-93
   PubMed Web of Science ®Google Scholar
• Lewis LD, Miller AA, Rosner GL, et al. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13(11):3302-11
   PubMed Web of Science ®Google Scholar
• Watters JW, Kraja A, Meucci MA, et al. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 2004;101(32):11809-14
   PubMed Web of Science ®Google Scholar
• Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004;75(5):448-54
   PubMed Web of Science ®Google Scholar
• Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001;39(12):517-28
   PubMed Web of Science ®Google Scholar
• Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001;48(2):115-22
   PubMed Web of Science ®Google Scholar
• Nallani SC, Goodwin B, Buckley AR, et al. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004;54(3):219-29
   PubMed Web of Science ®Google Scholar
• Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001;27(4):221-33
   PubMed Web of Science ®Google Scholar
• Baker SD. Drug interactions with the taxanes. Pharmacotherapy 1997;17(5 Pt 2):126S-132S
   Google Scholar
• Engels FK, Mathot RA, Loos WJ, et al. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006;5(7):833-9
   PubMed Web of Science ®Google Scholar
• Engels FK, Loos WJ, Mathot RA, et al. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemother Pharmacol 2007;60(4):569-79
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62(21):6158-64
   PubMed Web of Science ®Google Scholar
• Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 2007;13(9):2768-76
   PubMed Web of Science ®Google Scholar
• Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68(6):677-87
   PubMed Web of Science ®Google Scholar
• Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 2008;108(2):233-40 [Epub 2007 Apr 28]
   Google Scholar
• Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2007;103(2):197-208
   PubMed Web of Science ®Google Scholar
• Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002;3(5):341-5
   PubMedGoogle Scholar
• Martin M, Pienkowski T, MacKey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, O' Neill A, Sparano J, et al. E2197: phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005;23:512
   Google Scholar
• Sparano JA WM, Martino S, Jones V, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium; 2005 December 8 – 11; San Antonio, TX
   Google Scholar
• Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008;100(2):121-33
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20
   PubMed Web of Science ®Google Scholar
• Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7
   PubMed Web of Science ®Google Scholar
• Robert NJ EW, Pienkowski T, Crown J, et al. on behalf of the BCIRG 006 Investigators. BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. J Clin Oncol 2007;25(18S):[Abstract 19647]
   PubMedGoogle Scholar
• Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35(8):1194-201
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87(11):1210-5
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20(12):2812-23
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96(10):759-69
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91(12):1996-2004
   PubMed Web of Science ®Google Scholar
• Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22(2):254-61
   PubMed Web of Science ®Google Scholar
• Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16(4):602-10
   PubMed Web of Science ®Google Scholar
• Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006;17(3):467-72
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007;110(9):2027-34
   PubMed Web of Science ®Google Scholar
• Miller VA, Rigas JR, Francis PA, et al. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75(4):968-72
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21(16):3016-24
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001;33(2-3):277-87
   PubMed Web of Science ®Google Scholar
• Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23(33):8389-95
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25(11):1377-82
   PubMed Web of Science ®Google Scholar